Fortis press release ( FTS ): Q1 GAAP EPS of C$0.99. Capital expenditures of C$1.4 billion in the first quarter; C$5.6 billion annual capital plan on track. Outlook Fortis continues to enhance shareholder value through the execution of its capital plan, the balance and strength of its diversified portfolio of regulated utility businesses, and growth opportunities within and proximate to its servic...
Fortis press release ( FTS ): Q1 GAAP EPS of C$0.99. Capital expenditures of C$1.4 billion in the first quarter; C$5.6 billion annual capital plan on track. Outlook Fortis continues to enhance shareholder value through the execution of its capital plan, the balance and strength of its diversified portfolio of regulated utility businesses, and growth opportunities within and proximate to its service territories. The Corporation's C$28.8 billion five-year capital plan is expected to increase midyear rate base from C$42.4 billion in 2025 to C$57.9 billion by 2030, translating into a five-year compound annual growth rate of 7%. 3 Fortis expects its long-term growth in rate base will drive earnings that support dividend growth guidance of 4-6% annually through 2030. More on Fortis Inc. Fortis Inc. (FTS:CA) Q4 2025 Earnings Call Transcript Fortis Inc. 2025 Q4 - Results - Earnings Call Presentation Fortis Q1 2026 Earnings Preview ITC Holdings prices senior notes offering Historical earnings data for Fortis Inc.
Zalando SE press release ( ZLDSF ): Q1 net income of -€87.6M (vs. €9.9M in Q1/2025). Group revenue of €2,996.1M (+23.8% Y/Y). Group GMV grew by 6% on a pro-forma basis and 21.7% on a reported basis to €4.3B. Adjusted EBIT reached €65M, up 38.7% year-on-year, with the group adjusted EBIT margin improving from 1.9% to 2.2%. More on Zalando SE Zalando SE 2026 Q1 - Results - Earnings Call Presentation...
Zalando SE press release ( ZLDSF ): Q1 net income of -€87.6M (vs. €9.9M in Q1/2025). Group revenue of €2,996.1M (+23.8% Y/Y). Group GMV grew by 6% on a pro-forma basis and 21.7% on a reported basis to €4.3B. Adjusted EBIT reached €65M, up 38.7% year-on-year, with the group adjusted EBIT margin improving from 1.9% to 2.2%. More on Zalando SE Zalando SE 2026 Q1 - Results - Earnings Call Presentation Zalando SE (ZLNDY) Q4 2025 Press Conference Call Transcript Zalando SE 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Zalando SE Financial information for Zalando SE
Clear Secure press release ( YOU ): Q1 GAAP EPS of $0.38 beats by $0.03 . Revenue of $253M (+19.7% Y/Y) beats by $8.62M . Total CLEAR Members grew to 41.0 million, up 31.3% year-over-year and Active CLEAR+ Members grew to 8.2 million, up 13.0% year-over-year 60 CLEAR+ airports, and 277 retail locations with TSA PreCheck® Enrollment Provided by CLEAR as of March 31, 2026 eGates launched across 43 a...
Clear Secure press release ( YOU ): Q1 GAAP EPS of $0.38 beats by $0.03 . Revenue of $253M (+19.7% Y/Y) beats by $8.62M . Total CLEAR Members grew to 41.0 million, up 31.3% year-over-year and Active CLEAR+ Members grew to 8.2 million, up 13.0% year-over-year 60 CLEAR+ airports, and 277 retail locations with TSA PreCheck® Enrollment Provided by CLEAR as of March 31, 2026 eGates launched across 43 airports as of today; on track for network wide rollout in 2026 Second Quarter and Full Year 2026 Guidance Second quarter 2026 Revenue of $268-271 million vs $256.49M consensus, representing 22.8% year-over-year growth at the midpoint Second quarter 2026 Total Bookings of $280-285 million, representing 26.7% year-over-year growth at the midpoint Full Year 2026 Free Cash Flow guidance increased from at least $440 million to at least $465 million, representing at least 35.5% year-over-year growth Shares +2.3% PM. More on Clear Secure Clear Secure's Mass Adoption Moment Is Here (Rating Upgrade) Clear Secure: This Identity Verification Company Hits Another Inflection Point Clear Secure, Inc. (YOU) Q4 2025 Earnings Call Transcript Clear Secure Q1 2026 Earnings Preview Clear Secure raises dividend by 20% to $0.15
BeiGene press release ( ONC ): Q1 Non-GAAP EPADS of $3.24 Revenue of $1.51B (+34.8% Y/Y) beats by $70M . Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter Prior FY ...
BeiGene press release ( ONC ): Q1 Non-GAAP EPADS of $3.24 Revenue of $1.51B (+34.8% Y/Y) beats by $70M . Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter Prior FY 2026 Guidance Current FY 2026 Guidance1 Total revenue $6.2 - $6.4 billion $6.3 - $6.5 billion (vs. consensus of $ 6.38B ) GAAP gross margin % High-80% range High-80% range GAAP operating expenses2 (combined R&D and SG&A) $4.7 - $4.9 billion $4.7 - $4.9 billion GAAP operating income2 $700 - $800 million $750 - $850 million Non-GAAP operating income2,3 $1.4 - $1.5 billion $1.45 - $1.55 billion Click to enlarge More on BeiGene Tracking Baker Brothers Portfolio - Q4 2025 Update BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026 BeOne Medicines AG (ONC) Q4 2025 Earnings Call Transcript Most and least shorted mid-to mega-cap healthcare stocks in May BeiGene Q1 2026 Earnings Preview
Earnings Call Insights: Trevi Therapeutics (TRVI) Q1 2026 Management View CEO Jennifer Good said, "2026 is an important year of execution for the company," and tied the quarter’s focus to multiple trial starts across IPF-related chronic cough, non-IPF-ILD-related chronic cough, and refractory chronic cough (RCC). On IPF-related chronic cough, CEO Good said, "We expect to initiate the first of thos...
Earnings Call Insights: Trevi Therapeutics (TRVI) Q1 2026 Management View CEO Jennifer Good said, "2026 is an important year of execution for the company," and tied the quarter’s focus to multiple trial starts across IPF-related chronic cough, non-IPF-ILD-related chronic cough, and refractory chronic cough (RCC). On IPF-related chronic cough, CEO Good said, "We expect to initiate the first of those 2 studies this quarter, followed by the second study in the second half of this year," after what she described as "our positive FDA meeting in the first quarter." On non-IPF-ILD-related chronic cough, CEO Good said Trevi will "submit a meeting request and protocol to the FDA" and "propose an adaptive Phase II/III study," adding, "If all goes as proposed to the FDA, we expect to initiate this trial in the second half of the year." On RCC, CEO Good said the company expects to initiate "a Phase IIb parallel arm dose-ranging trial with 3 doses and placebo this quarter," and added the study’s "sample size reestimation or SSRE" is expected to read out "in the fourth quarter of this year." CFO David Hastings emphasized funding and financing execution: "We ended the first quarter of 2026 with approximately $172 million in cash, cash equivalents and marketable securities," and noted this excludes "the $162 million in net proceeds" from the April 2026 equity offering. CFO Hastings said the offering supported two objectives: "we removed any financial overhang" and "we extended our cash runway into 2030," while also stating the runway guidance includes funding IPF-related chronic cough development "potentially through FDA approval." Outlook Management’s timing focus centered on trial initiations and interim milestones rather than revenue or EPS guidance, including CEO Good’s expectation to start the first IPF Phase III study in Q1 2026 and the second IPF study in H2 2026, and to start RCC Phase IIb in Q1 2026 with SSRE in Q4 2026. Compared with the prior quarter, the most material u...
Amcor press release ( AMCR ): Q3 Non-GAAP EPS of $0.96 beats by $0.01 . Revenue of $5.91B (+77.5% Y/Y) beats by $170M . Fiscal 2026 Guidance: Adjusted EPS $3.98 to $4.03, growth of ~12% at the midpoint; Mitigating impact of Middle East conflict Free Cash Flow revised to be $1.5-1.6 billion Shares +1.5% PM. More on Amcor Amcor: Dividend Aristocrat With A Great Yield And Below Fair Value Amcor: A De...
Amcor press release ( AMCR ): Q3 Non-GAAP EPS of $0.96 beats by $0.01 . Revenue of $5.91B (+77.5% Y/Y) beats by $170M . Fiscal 2026 Guidance: Adjusted EPS $3.98 to $4.03, growth of ~12% at the midpoint; Mitigating impact of Middle East conflict Free Cash Flow revised to be $1.5-1.6 billion Shares +1.5% PM. More on Amcor Amcor: Dividend Aristocrat With A Great Yield And Below Fair Value Amcor: A Defensive Value Play In Packaging Amcor: 'Buy' While The Market Undervalues This Income Stock (Downgrade) Amcor Q3 2026 Earnings Preview Strait of Hormuz disruptions send global plastics prices soaring
British International Investment intends to tap £7 billion ($9.45 billion) held by insurers, pension and sovereign wealth funds as co-investment into various projects globally over the next five years. In total, the UK’s development finance institution will invest £15 billion over that period, according to Chief Executive Officer Leslie Maasdorp . BII will provide £8 billion of the amount, with th...
British International Investment intends to tap £7 billion ($9.45 billion) held by insurers, pension and sovereign wealth funds as co-investment into various projects globally over the next five years. In total, the UK’s development finance institution will invest £15 billion over that period, according to Chief Executive Officer Leslie Maasdorp . BII will provide £8 billion of the amount, with the remainder coming from pooled domestic savings, he said in an interview. About 60% of the planned outlay will be in Africa primarily targeting infrastructure, financial services, climate change and sustainability-linked businesses. The continent’s insurers, pensions and sovereign funds are estimated to hold $4 trillion of assets. “The single biggest metric that will define the next five years for BII and development finance more generally is the mobilization of domestic capital,” Maasdorp said in the Kenyan capital, Nairobi. “One of the key areas of funding that we are now working on is to mobilize and crowd-in more domestic pools of capital.” Currently, the bulk of available capital in Africa is allocated to government securities, with assets under management in capital markets seen nearly tripling to $7 trillion by 2040, according to financial markets development agency FSD Africa . UK Development Arm Aims to Invest £15 Billion Over Five Years Global Shocks Seen Spurring African Pivot to Domestic Capital African Assets Under Management Seen at $7 Trillion by 2040 On an average annual basis, BII’s rate of return on investments is about 5%. BII is investing in energy, which it expects will be the most important contributor to transformation on the continent. About 80% of the people who live without electricity globally reside in Africa, Maasdorp said. The agency has a 70% equity stake in power projects developer Globeleq and wholly owns transmission company Gridworks Development Partners LLP . “Without power, the African continent will not develop and really reach its full...
Novo Nordisk CEO Mike Doustdar discusses the drugmaker's Wegovy obesity pill which fueled sales in the first quarter. Novo is "very optimistic" on the medication despite competition from Eli Lilly, Doustdar tells Bloomberg Television, and the firm doesn't anticipate any price reductions. (Source: Bloomberg)
Novo Nordisk CEO Mike Doustdar discusses the drugmaker's Wegovy obesity pill which fueled sales in the first quarter. Novo is "very optimistic" on the medication despite competition from Eli Lilly, Doustdar tells Bloomberg Television, and the firm doesn't anticipate any price reductions. (Source: Bloomberg)